The largest randomized, controlled, double-blind trial of psilocybin ever (from Compass Pathways) found that a single higher dose led to a rapid and long-lasting decrease in depression symptoms; patients given the highest dose (25 mg) had a significant decline in depression compared to those receiving a microdose of 1 mg. 29% of patients in the highest-dose group were free from depression three weeks after treatment (compared to 7.6% in the control group), and more than a quarter of the high-dose patients were still in remission three months later. These are important findings, as 100 million people worldwide suffer from treatment-resistant depression.
Access this study
With a new era for psychedelics, it will be a key topic at the Global Wellness Summit. Rick Doblin, PhD, founder, Multidisciplinary Association for Psychedelic Studies (MAPS) will speak on “What a Trip: Psychedelics Have Their Moment!” and Louie Schwartzberg, founder and filmmaker, Moving Art, will address “The Treatment Revolution: Psychedelics, Nature and Healing.”